Edition:
United States

Oxford BioMedica PLC (OXB.L)

OXB.L on London Stock Exchange

8.40GBp
--
Change (% chg)

-- (--)
Prev Close
8.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
7,865,030
52-wk High
11.50
52-wk Low
3.31

Chart for

About

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company's segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners. The R&D... (more)

Overall

Beta: 0.05
Market Cap(Mil.): £260.99
Shares Outstanding(Mil.): 3,107.07
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 197.02 15.79
EPS (TTM): -- -- --
ROI: -- -10.12 12.01
ROE: -- -37.71 15.91

RPT-Profit on $475,000 Novartis cancer drug could be a while coming

ZURICH, Aug 31 Novartis's new gene-modifying cancer therapy's $475,000-per-patient sticker price has drawn fire from advocate groups calling for cheaper drugs, but analysts said the Swiss drugmaker could initially struggle to break even.

Sep 01 2017

Profit on $475,000 Novartis cancer drug could be a while coming

ZURICH Novartis's new gene-modifying cancer therapy's $475,000-per-patient sticker price has drawn fire from advocate groups calling for cheaper drugs, but analysts said the Swiss drugmaker could initially struggle to break even.

Aug 31 2017

Profit on $475,000 Novartis cancer drug could be a while coming

ZURICH, Aug 31 Novartis's new gene-modifying cancer therapy's $475,000-per-patient sticker price has drawn fire from advocate groups calling for cheaper drugs, but analysts said the Swiss drugmaker could initially struggle to break even.

Aug 31 2017

BRIEF-Oxford Biomedica says Stuart Paynter joins group as CFO

* STUART PAYNTER TODAY JOINS GROUP AS CHIEF FINANCIAL OFFICER AND MEMBER OF BOARD OF DIRECTORS

Aug 29 2017

Oxford BioMedica wins big contract for Novartis cell therapy

LONDON Novartis has signed a major contract with Oxford BioMedica that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with material for its novel cell therapy CTL019.

Jul 06 2017

Oxford BioMedica wins big contract for Novartis cell therapy

LONDON, July 6 Novartis has signed a major contract with Oxford BioMedica that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with material for its novel cell therapy CTL019.

Jul 06 2017

BRIEF-Oxford Biomedica completes new $55 million debt facility

* Completed a new $55 million debt facility with Oaktree Capital Management - Strategic Credit Strategy

Jun 30 2017

Earnings vs. Estimates